Brendan Hannah

Brendan Hannah

Chief Operating Officer, Chief Business Officer and Chief Compliance OfficeratIRulya Therapeutics· In proxies 2022–2025

Pay in FY2025-8% from the year before · IRulya Therapeutics stock +79.1% the same year

Brendan Hannah was paid $1.3M in FY2025 (Dec), down 8%. IRulya Therapeutics stock rose 79.1% that year.

Pay$100 in the stock at the end of FY21 → $27
Pay is from the Summary Compensation Table of each IRulya Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. IRulya TherapeuticsPublic company · 4 yr
    • Chief Operating Officer, Chief Business Officer and Chief Compliance Officer2022 – Present · 4 yrStock in role -99%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?